Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain

References

• World Health Organization. The World Health Report 2003 – Shaping the Future. Available from http://www.who.int/whr/2003/en/ [Accessed 22 May 2005]
   Google Scholar
• Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26: 917–32
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost- effectiveness of interventions in diabetes mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5–26
   PubMed Web of Science ®Google Scholar
• Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Australian Government Publishing Service, Canberra, 1995
   Google Scholar
• Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario Ministry of Health, Ottawa, 2002
   Google Scholar
• Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 1997;41:105–19
   PubMed Web of Science ®Google Scholar
• Commonwealth Department of Health and Ageing. Pharmaceutical Benefits Schedule (PBS), PBS Codes: 2580T, 2578Q, 2958Q, 2507Y, 1508J. Commonwealth Department of Health and Ageing, Canberra, 2004
   Google Scholar
• eMIMS. Monthly Index of Medical Specialties, 2004. Available from http://www.emims.net [Accessed 22 May 2005]
   Google Scholar
• Commonwealth Department of Health and Ageing. National Hospital Data Collection Cost Report Round 7, version 4.2 (2001–02), Public Sector Estimated Costs Weights, Cost Weights for AR-DRG (Australian Refined Diagnostic Related Groups). Commonwealth Department of Health and Ageing, Canberra, 2003
   Google Scholar
• Dewey HM, Thrift AG, Mihalopoulos C, et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001;32:2409–16
   PubMed Web of Science ®Google Scholar
• Australia and New Zealand Dialysis and Transplant Report (ANZDATA). ANZDATA Registry Report 2004, The 27th Annual Report. Adelaide, South Australia, 2003
   Google Scholar
• Victorian Government Department of Human Services (DHS). Victoria Public Hospitals and Mental Health Services Policy and Funding Guidelines 2002–2003. Section B – Conditions of Funding. Victorian Government Department of Human Services (DHS), Melbourne, 2002
   Google Scholar
• The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1468–78
   PubMed Web of Science ®Google Scholar
• Commonwealth Department of Health and Ageing. Manual of Resource Items and their Associated Costs, for use in submissions to Pharmaceutical Benefits Advisory Committee involving economic analysis. Appendix 3, Hospital Services, Outpatient Service Costs per AAC (Australian Ambulatory Classes), AAC Codes 30, 73 and 74. Commonwealth Department of Health and Ageing, 2002. Available from http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs-general-pubs-manual-content.htm [Accessed 26 July 2005]
   Google Scholar
• Australian Department of Veterans’ Affairs. Schedule of fees for community nursing providers – public sector, 2005. Available from http://www.dva.gov.au/health/provider/community_nursing/guidelines/Sect2_5.htm [Accessed 26 July 2005]
   Google Scholar
• National Health and Medical Research Council. Management of Diabetic Retinopathy: Clinical Practice Guidelines. National Health and Medical Research Council, Canberra, 1997
   Google Scholar
• Commonwealth Department of Health and Ageing. Medicare Benefits Schedule (MBS), May 2004; MBS Codes T1.7 (13839), 65070, A5 (23). Commonwealth Department of Health and Ageing, Canberra, 2005
   Google Scholar
• Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in Australia. Clin Experiment Ophthalmol 2000;28:140–2
   PubMed Web of Science ®Google Scholar
• Department of Health and Ageing. The Residential Care Manual. Aged and Community Care Division. December 2001 Edition; Department of Health and Ageing, Canberra, 2002. Available from http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ageing-manuals-rcm-rcmindx1.htm [Accessed 26 July 2005]
   Google Scholar
• Department of Family, and Community Services, Department of Education SaT,, and Department of Employment and Workplace Relations. A Guide to Australian Government Payments, Canberra, 2004. Available from http://www.centrelink.gov.au/internet/internet.nsf/filestores/co029_0507/$file/co029_0507en.pdf [Accessed 22 May 2005]
   Google Scholar
• Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2003;20\(Suppl 1):31–42
   Google Scholar
• O’Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3: 7–18
   Google Scholar
• Ontario Ministry of Health. The Ontario Case Cost Program Database, Toronto, 1994–1996
   Google Scholar
• Statistics Canada. Ottawa, 2000. Available from http://www.statcan.ca [Accessed 22 May 2005]
   Google Scholar
• Levy AR, Briggs AH, Demers C, et al. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 2001;142:537–43
   PubMed Web of Science ®Google Scholar
• Curtis JR, To T, Muirhead S, et al. Recent trends in hospitalization for diabetic ketoacidosis in Ontario children. Diabetes Care 2002;25:1591–6
   PubMed Web of Science ®Google Scholar
• Harris SB, Meltzer SJ, Zinman B. New guidelines for the management of diabetes: a physician’s guide. Steering Committee for the Revision of the Clinical Practice Guidelines for the Management of Diabetes in Canada. CMAJ 1998;159:973–8
   Google Scholar
• Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case – control study. Ann Intern Med 1992;117:97–105
   Google Scholar
• Ontario Ministry of Health. Ontario Ministry of Health Drug Formulary, Toronto, 2004. Available from http://www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html [Accessed 22 May 2005]
   Google Scholar
• Canada RX. Canada Drug Price Search 2005. Available from http://canadarx.com/search.html [Accessed 22 May 2005]
   Google Scholar
• Government of Alberta. Workers’ Compensation Board: Alberta Physician Fee Schedule. Government of Alberta, Edmonton, 1999. Available from http://www.wcb.ab.ca/pdfs/physfee_sched.pdf [Accessed 22 May 2005]
   Google Scholar
• Fagnani F, Souchet T, Labed D. Incidence, management and cost of cardio-vascular and renal complications in French type 2 diabetic patients in 2001. Value Health 2002;5: 206
   Google Scholar
• Levy P, Lechat P, Leizorovicz A, et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998;12:301–5
   PubMed Web of Science ®Google Scholar
• Mullins CD, Sikirica M, Seneviratne V, et al. Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004;22:1001–14
   PubMed Web of Science ®Google Scholar
• LePen C, Lilliu H, Keller T, et al. The economics of TRACE. A cost-effectiveness analysis of trandolapril in post-infarction patients with left ventricular dysfunction. Pharmacoeconomics 1998;14:49–58
   Google Scholar
• Grueger J, O’Brien B, Caro J, et al. The lifetime direct medical costs of managing diabetes and its complications in France. Value Health 2001;4:504–5
   Google Scholar
• Programme de médicalisation des systèmes d’information (PMSI). French Ministry of Health, Merginac, 2004. Available from http://www.caducee.net/DossierSpecialises/systemeinformation-sante/pmsi.asp [Accessed 22 May 2005]
   Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003;18:2059–66
   PubMed Web of Science ®Google Scholar
• Cogny F, Ngohou C, Ponterfact R, et al. Insuffisance rénale terminale, Gestions Hospitalières, Paris, 1995
   Google Scholar
• Nghiem-Buffet MH, de Pouvourville G, Renard G, et al. [Cost of managing cataracts. Evaluation of traditional hospitalization and ambulatory surgery]. Presse Med 2001;30:1924–6
   Google Scholar
• Bonastre J, Le Pen C, Soubrane G, et al. The burden of age- related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21:181–90
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767–78
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Sendi PP, Roze S, et al. Comparaison du rapport coût-efficacité du contrôle strict de la glycémie par la metformine ou par une stratégie conventionnelle dans le système de soin français chez des diabétiques de type 2 présentant une surcharge pondérale. Journal d’Economie Medicale 2002;1:45–58
   Google Scholar
• Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004;22:321–41
   PubMed Web of Science ®Google Scholar
• Banz K, Dinkel R, Hanefeld M, et al. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decision- analytical approach. Pharmacoeconomics 1998;13:449–59
   Google Scholar
• Statistisches Bundesamt Deutschland. Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland 1998 (7.8) [Stuttgart: Metzler Poeschel, 1998:410–3], 2005
   Google Scholar
• Krankenhausdiagnosestatistik: diagnosedaten der krankenhauspatienten von 1997. Wiesbaden: Statistisches Bundesamt Deutchland, 1999
   Google Scholar
• CIBIS-II Investigators, Health Economics Group. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J 2001;22:1021–31
   Google Scholar
• Rychlik R, Pfiel T, Daniel D, et al. Socioeconomic relevance of treatment of chronic heart failure stage NYHA 2 with crataegus extract WS 1442 – a prospective 3-year pharmacoeconomic study. Value Health 2004;7:695
   Web of Science ®Google Scholar
• Laaser U, Breckenkamp J, Niermann U. Cost-effectiveness analysis of medical interventions in patients with stroke in Germany under special consideration of ‘stroke units’. Gesundh okon Qual Manag 1999;4:176–83
   Google Scholar
• Statistisches Bundesamt Deutschland;. Preisindizes für die Lebenshaltung. Gesundheitsbericht fur Deutschland. Statistisches Bundesamt Deutschland 1998 (5.23) [Stuttgart: Metzler Poeschel, 1998:254–8], 2005
   Google Scholar
• Schadlich PK, Brecht JG, Brunetti M, et al. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 2001;19:497–512
   PubMed Web of Science ®Google Scholar
• Köhler A, Hess R. Kölner Kommentar zum EBM 2002. Köln: Deutscher Ärzte-Verlag, 2002
   Google Scholar
• Kelm-Kahl I, Ohrloff C. Minimal invasive Chirurgie beim Grauen Star: Was zahlt die Kassee- Medizin and Gesdunheit. [1.10.2001]. Frankfurt, 2001. Available from http://www3.lifeline.de/yavivo/Verfahren/Augenheilkunde/Katarakt/35kosten.html [Accessed 22 May 2005]
   Google Scholar
• Szucs TD, Smala A, Fischer T. [Costs of intensive insulin therapy in type 1 diabetes mellitus: experiences from the DCCT study]. Fortschr Med 1998;116: 34–8
   Google Scholar
• Dahmen HG. [Diabetic foot syndrome and its risks: amputation, handicap, high-cost sequelae]. Gesundheitswesen 1997;59:566–8
   PubMedGoogle Scholar
• Ghatnekar O. Cost-effectiveness of treating deep diabetic foot ulcers with promogran in four different European countries. J Wound Care 2002;11:70–4
   PubMedGoogle Scholar
• Ministero della Sanita. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera di cui al DecretoMinisteriale 12 dicembre 1994. Ministero della Sanita 1997; Suppl ord. alla G.U.(209)
   Google Scholar
• Ministero della Sanita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitorio Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996. Suppl. ord. Alla G.U. n.216, 14 settembre 1996
   Google Scholar
• Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651–9
   Google Scholar
• Bastida J, Aguilar S, Alvarez M, et al. The economic burden of stroke in Spain. Value Health 2003;6:614
   Web of Science ®Google Scholar
• Lamas J, Alonso M, Saavadra J, et al. Costes de la dialisis cronica en un hospital publico mitos y realidades. Nefrologia 2002;22:269–76
   PubMedGoogle Scholar
• Palmer AJ, Annemans L, Roze S, et al. Cost-Effectiveness of Irbesartan in Patients with Type 2 Diabetes, Hypertension and Nephropathy: A Spanish Perspective. Nefrologia 2004;24:231–8
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad de Consumo, Institute de Salud Carlos III. Analisis coste-efectividad de diferentes estrategias para el cribado y tratamiento de la retinopatia diabetica en pacientes con diabetes mellitus. Min de Sanidad Consumo, Madrid 2004;00/10116
   Google Scholar
• Rubio-Terres C, Rodriguez J, Bolinder B, et al. Cost-utility analysis of insulin glargine compared with NPH insulin in patients with type 1 diabetes in Spain. Diabetes 2004;53:A291–2
   Google Scholar
• Hart WM, Espinosa C, Rovira J. A simulation model of the cost of the incidence of IDDM in Spain. Diabetologia 1997;40:311–8
   Google Scholar
• Reparaz L, Martinez I, Ligero J. Epidemiologia y analisis cost/efectividad de la angiopatia diabetica en cirugia vascular. Angiologia 1992;6:225–33
   Google Scholar
• Calle-Pascual AL, Redondo MJ, Ballesteros M, et al. Nontraumatic lower extremity amputations in diabetic and non-diabetic subjects in Madrid, Spain. Diabetes Metab 1997;23:519–23
   Google Scholar
• Oliva J, Lobo F, Molina B, et al. Direct healthcare costs of diabetes mellitus in Spain. Working Paper 03–68. Economics series 27. Nov 2003. Universidad Carlos III de Madrid
   Google Scholar
• Sacristan J, Gomis R, Maranes JP, et al. Cost-effectiveness of insulin lispro versus regular insulin in patients with type 1 diabetes, based on severe hypoglycemia occurrence. Diabetes 2000;49(Suppl 1):924–P
   Google Scholar
• Porta M, Rizzitiello A, Tomalino M, et al. Comparison of the cost-effectiveness of three approaches to screening for and treating sight-threatening diabetic retinopathy. Diabetes Metab 1999;25:44–53
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness analysis of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: the Italian perspective. Pharmacoeconomics – Italian Research Articles 2004;7:41–55
   Google Scholar
• Legge 18/1980. Indennita di accompagnamento agli invalidi civili totalmente inabili. independent Pubblicata su G.U. n. 44). 2–14–1980
   Google Scholar
• Le Pen C, Berdeaux G. Diagnosis related group costs in a regulated environment. A note about their economic interpretation. Pharmacoeconomics 2000;17:115–20
   Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30
   PubMed Web of Science ®Google Scholar
• Detournay B, Fagnani F, Pribil C, et al. [Medical resources consumption of type 2 diabetics in France in 1998]. Diabetes Metab 2000;26:225–31
   PubMed Web of Science ®Google Scholar
• Lucioni C, Garancini MP, Massi-Benedetti M. The costs of type 2 diabetes mellitus in Italy. A Code-2 Sub-Study. Treat Endocrinology 2003;2: 121–33
   Google Scholar
• Mata M, Antonanzas F, Tafalla M, et al. [The cost of type 2 diabetes in Spain: the CODE-2 study]. Gac Sanit 2002;16:511–20
   PubMedGoogle Scholar
• Liebl A, Neiss A, Spannheimer A, et al. [Costs of type 2 diabetes in Germany. Results of the CODE-2 study]. Dtsch Med Wochenschr 2001;126: 585–9
   Google Scholar
• Grover S, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45–50
   PubMed Web of Science ®Google Scholar
• Wendland G, Klever-Deichert G, Lauterbach K. [Cost effectiveness of lipid lowering therapy]. Herz 2001;26:552–60
   PubMed Web of Science ®Google Scholar
• Tàrrage-Lopez PJ, Celda-Rodriguez À, Cerdàn-Oliver M, et al. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain. Pharmacoeconomics 2005;25:275–87
   Google Scholar
• Salve Locs Italia. l’Aspirina, Salve Locs Italia. Salve Locs (Italy). 2005
   Google Scholar
• Vidal. Vidal, L’information de référence sur les produits de santé. 2004. Available from http://www.vidal.fr [Accessed 22 May 2005]
   Google Scholar
• Gozzoli V, Palmer AJ, Brandt A, et al. [Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients]. Dtsch Med Wochenschr 2000;125:1154–9
   PubMedGoogle Scholar
• OEMF. Informatone Farmaceutico (marzo 2003) (Aggiornamento). Milano. 2004. Available from http://www.oemf.it [Accessed 10 December 2004]
   Google Scholar
• Darba J, Izquierdo I, Pontes C, et al. Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. Pharmacoeconomics 2002;20:195–201
   PubMed Web of Science ®Google Scholar
• Cnamts. La Classification Commune des Actes Médicaux (CCAM). 2002
   Google Scholar
• Base de Datos de Costes Sanitarios, 2004. Soikos, Centro de Estudios en Economía de la salud y Política Social S.L, Barcelona, 2004
   Google Scholar
• Zentralinstitut für die kassenärztliche Versorgung. 1998. Behandlungsprofil für Diabetes Mellitus, 2002. Available from http://www.zi-koeln.de [Accessed 22 September 2003]
   Google Scholar
• Nebel M. Behandlungskosten der Nierenersatztherapie in Deutschland 1999. Nieren – und Hochdruckkrankheiten. 2002;31:85–92
   Google Scholar
• Wezel H, Liebold R. Handkommenentar zum einheitlichen bewertungsmassstab fur arztliche leistungen (EBM) Items 1, 2,10, 60. Sankt-Augustin: Asgard-Verlag, 2001
   Google Scholar
• Lucioni C, Mazzi S, Neeser K. Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics 2004; 6:81–93
   Google Scholar
• KVSA. Kassenarztlichen Vereiningung Sachen Anhalt 2001. Available from http://www.kvsa.de/pub/recht/anl.pdf [Accessed 10 December 2004]
   Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. Dtsch Med Wochenschr 2004;129:13–18
   PubMed Web of Science ®Google Scholar
• Berto P, Munro V, Gaddi A, et al. Cost-effectiveness Analysis for Statin Therapies in Primary Prevention of Coronary Heart Disease in Italy. Clin Drug Invest 2000;20:109–121
   PubMed Web of Science ®Google Scholar
• Smurawska LT, Alexandrov AV, Bladin CF, et al. Cost of acute stroke care in Toronto, Canada. Stroke 1994;25:1628–31
   PubMed Web of Science ®Google Scholar
• GioFil. Il Portale dell’Informazione Sanitaria Farmaceutica. Available from http://www.giofil.it [Accessed 22 September 2004]
   Google Scholar
• Federazione Nazionale Unitaria dei Titolari di Farmacia Itatliani Available from: http://www.federfarma.it [Accessed 22 September 2004]
   Google Scholar
• Abraham C, Priest L. Crisis in cataract surgery epitomizes waiting-list woes. Globe and Mail, 11 September 2004
   Google Scholar
• Ontario Ministry of Health and Long-term Care. Ontario Health Premium, Toronto 2004. Available from: http://www.health.gov.on.ca/healthpremium/fact_sheet.html [Accessed 22 May 2005]
   Google Scholar
• Castells X, Alonso J, Castilla M, et al. Outcomes and costs of outpatient and inpatient cataract surgery: a randomised clinical trial. J Clin Epidemiol 2001;54:23–9
   PubMed Web of Science ®Google Scholar